Aspirin dosing in cardiovascular disease prevention and management: an update

Journal of Thrombosis and Thrombolysis
Leila Ganjehei, Richard C Becker

Abstract

Aspirin has been in use for prevention and management of cardiovascular diseases for several decades. Clinical and epidemiological literature suggests that while net benefits of aspirin in primary prevention of CVDs are less clear, the benefits of aspirin in acute scenarios and secondary prevention settings are well established. However, its optimum dosing requirements have been up for debate especially in various settings of acute coronary syndrome and stable ischemic heart disease. The role of clinician in stratifying individual risk score to achieve net clinical benefit is an important determinant of initiating aspirin therapy. The purpose of this article is to review association of aspirin and CVD in general, and to review its dosing regimens in acute settings as well as primary and secondary prevention as suggested by various established guidelines. We also aim to provide the readers an update on recent changes and current evidence based practice trends.

References

Jan 30, 1988·British Medical Journal·R PetoS Norton
Jun 1, 1982·The Journal of Clinical Investigation·P PatrignaniC Patrono
Mar 14, 1998·Circulation·S HusainA A Quyyumi
Mar 15, 2000·Circulation·E H Awtry, J Loscalzo
Dec 22, 2000·BMJ : British Medical Journal·W Sneader
Jan 16, 2002·Annals of Internal Medicine·UNKNOWN U.S. Preventive Services Task Force
Nov 1, 2003·Thrombosis Research·J R Vane, R M Botting
Mar 9, 2005·The New England Journal of Medicine·Paul M RidkerJulie E Buring
Jan 18, 2006·American Journal of Preventive Medicine·Umed A AjaniAli H Mokdad
Jan 19, 2006·JAMA : the Journal of the American Medical Association·Jeffrey S BergerDavid L Brown
Feb 24, 2006·The American Journal of Medicine·James E Dalen
Jun 17, 2006·American Journal of Preventive Medicine·Michael V MaciosekLeif I Solberg
May 10, 2007·JAMA : the Journal of the American Medical Association·Charles L CampbellSteven R Steinhubl
Mar 19, 2009·Annals of Internal Medicine·UNKNOWN US Preventive Services Task Force
Jan 26, 2011·Circulation·Paul A HeidenreichUNKNOWN Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research
Feb 24, 2011·Circulation·Valentin Fuster, Joseph M Sweeny
Apr 5, 2011·The Canadian Journal of Cardiology·Alan D BellJean-François Tanguay
Oct 25, 2011·European Heart Journal·Carlo PatronoFreek Verheugt
Jan 11, 2012·Archives of Internal Medicine·Sreenivasa Rao Kondapally SeshasaiKausik K Ray
Jan 20, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Ayman El-MenyarJassim Al Suwaidi
Aug 28, 2012·European Heart Journal·UNKNOWN Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Doron Zahger
Sep 29, 2012·Pharmacotherapy·Carrie W NemerovskiLynette R Moser
May 17, 2013·Drugs·Rubén Casado-ArroyoAngel Lanas

❮ Previous
Next ❯

Citations

Jun 21, 2016·Expert Opinion on Drug Metabolism & Toxicology·Ezekiel Uba Nwose, Kwang Choon Yee
Oct 28, 2019·Frontiers in Physiology·Alice Miriam KitayJohn Peter Geibel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease
Oliver SchnellMichael Hummel
© 2021 Meta ULC. All rights reserved